The Prospect of Treating Rheumatoid Arthritis with Recombinant Human Interleukin-1 Receptor Antagonist

Author： Bresnihan B.  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.15, Iss.2, 2001-02, pp. : 87-97

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Polymorphism of interleukin-1 receptor antagonist gene and obesity

By Um J.-Y.   Lee K.-M.   Kim H.-M.  

Clinica Chimica Acta, Vol. 340, Iss. 1, 2004-02 ,pp. : 173-177

Elsevier

Access to resources Recommend Favorite

Differential effect of benzydamine on pro- versus anti-inflammatory cytokine production: lack of inhibition of interleukin-10 and interleukin-1 receptor antagonist

By Sironi M.  

International Journal of Clinical & Laboratory Research, Vol. 30, Iss. 1, 2000-03 ,pp. : 17-19

Springer Publishing Company

Access to resources Recommend Favorite

Rituximab: In Rheumatoid Arthritis

By Frampton James E.   Scott Lesley J.  

BioDrugs, Vol. 21, Iss. 5, 2007-01 ,pp. : 333-341

Adis International

Access to resources Recommend Favorite

Abatacept for rheumatoid arthritis

By Rojahn Ruth  

International Journal of Evidence-based Healthcare, Vol. 9, Iss. 4, 2011-12 ,pp. : 456-457

Blackwell Publishing

Access to resources Recommend Favorite

Certolizumab Pegol: In Rheumatoid Arthritis

By Duggan Sean T.   Keam Susan J.  

BioDrugs, Vol. 23, Iss. 6, 2009-12 ,pp. : 407-417

Adis International

Access to resources Recommend Favorite